Increased risk for myocarditis, pericarditis seen one to two weeks after COVID-19 mRNA vaccination
Substantial Mortality Benefits Expected From Optimal Medication Use for HFrEF
1,188,277 deaths could potentially be prevented over 12 months with optimal implementation of quadruple guideline-directed medical therapy